Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 17, 2022 | Series C | $57M | 1 | — | — | Detail |
| Jan 8, 2019 | Series B | $63M | 1 | — | — | Detail |
| Dec 31, 2015 | Series A | $5M | 1 |
Novo Nordisk
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Novo Nordisk
|
— | Series C |
Dexcom
|
— | Series B |